Form 4 for XENE Xenon Pharmaceuticals Inc.
Accepted 2026-06-03 21:04:00 ET · period of report 2026-06-01 · accession 0001193125-26-256121 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-03 21:04 | 2026-06-01 | XENE | GANNON STEVEN | Dir | M - OptEx | — | +2,645 | 13.3K | +25% | — |
| D | 2026-06-03 21:04 | 2026-06-01 | XENE | GANNON STEVEN | Dir | F - Tax | $53.41 | -1,416 | 11.9K | -11% | -$75.6K |
| D | 2026-06-03 21:04 | 2026-06-01 | XENE | GANNON STEVEN | Dir | M - OptEx | $0.00 | -2,645 | 0 | -100% | $0 |
| DM | 2026-06-03 21:04 | 2026-06-03 | XENE | GANNON STEVEN | Dir | A - Grant | $0.00 | +12.1K | 1,593 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-06-01 | M | A | 2,645 | — | 13,286 | D | — | — | (F1) Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. (F1) Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. |
| 2 | Common | Common Shares | 2026-06-01 | F | D | 1,416 | $53.41 | 11,870 | D | — | — | (F2) Represents the number of Common Shares withheld by the issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of the RSUs, and does not represent a sale. (F3) Represents the closing price of Common Shares on June 1, 2026 for purposes of net settlement calculations. |
| 3 | Derivative | Restricted Share Units | 2026-06-01 | M | D | 2,645 | $0.00 | 0 | D | — · — to — | 2,645 Common Shares | (F1) Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. (F1) Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. (F1) Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. |
| 4 | Derivative | Share Option (Right to Buy) | 2026-06-03 | A | A | 10,507 | $0.00 | 10,507 | D | $53.46 · — to 2036-06-02 | 10,507 Common Shares | (F4) Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. |
| 5 | Derivative | Restricted Share Units | 2026-06-03 | A | A | 1,593 | $0.00 | 1,593 | D | $0.00 · — to — | 1,593 Common Shares | (F5) Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. (F5) Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. |